TNFSF10 and cancer: In addition, in contrast to several chemotherapeutic drugs, which potentiate TRAIL activity via upregulation of either DR4 or DR5 [16, 17], our results indicate that the relative expression of TRAIL death and TRAIL decoy receptors is not the factor, at least in MDA-MB-435 cells, which restores TRAIL sensitivity in either ML100- or NSC130362-treated cancer cells.